BIS News and Press, ProShares UltraShort Nasdaq Biotechnology From 06/09/21

Historic efforts to develop COVID-19 vaccines have had two huge effects on the industry. Efforts to waive patents on COVID-19 vaccines to help reduce costs for emerging markets are also stuck. Since healthcare is an industry that has a profound impact on society, there’s a ...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

If two strategies or portfolios are correlated highly enough (higher than 0.84), then their types of risk overlap sufficiently to be part of the same asset class or to serve the same strategic purpose in a portfolio. The demand for acute care has an inelastic demand curve, meaning tha...

Gainers:  S&P Biotech Bull 3X Direxion (NYSEARCA: LABU )   +35.9% . More news on: Direxion Daily S&P Biotech Bull 3x Shares ETF, Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X Shares, ProShares Trust II - ProShares Ultra Bloomberg Crude...

Q&A on Splits and Reverse Splits ProShares, a premier provider of ETFs, announced today forward and reverse share splits on eleven of its ETFs. The splits will not change the total value of a shareholder's investment. Forward Splits Five ETFs will forward split their shar...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

Gainers:  Direxion S&P Biotech Bull 3X (NYSEARCA: LABU )  +27.4% . More news on: Direxion Daily S&P Biotech Bull 3x Shares ETF, Direxion Daily CSI China Internet Index Bull 2x Shares ETF, ProShares Trust - ProShares Ultra Nasdaq Biotechnology, News on ETFs, Stocks on th...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications. ACADIA is well prepared financially and has t...

High drug prices will, again, be a key issue in the 2020 Presidential campaign considering that President Trump has made scant progress on the matter despite much rhetoric. More news on: Eli Lilly and Company, Merck & Co., Inc., Amgen Inc., Healthcare stocks news, , News on ETFs, R...